Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 71
- Registration Number
- NCT04974216
- Locations
- 🇧🇪
Clinique Universitaire Saint LUC, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪CHRU Mont Godinne, Yvoir, Belgium
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Juan Du
- Target Recruit Count
- 90
- Registration Number
- NCT04941937
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04938297
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-11-23
- Target Recruit Count
- 17
- Registration Number
- NCT04934579
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-11-07
- Target Recruit Count
- 289
- Registration Number
- NCT04922567
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT04903197
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
- Conditions
- Interventions
- Biological: Belantamab MafodotinBiological: DaratumumabDrug: LenalidomideDrug: DexamethasoneOther: Quality-of-Life AssessmentProcedure: Biospecimen CollectionProcedure: Skeletal Survey X-RayProcedure: Low Dose Computed Tomography of the Whole BodyProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 5
- Registration Number
- NCT04892264
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 198
- Registration Number
- NCT04891809
- Locations
- 🇷🇸
University Clinical Center Kragujevac, Clinic for Hematology, Kragujevac, Serbia
🇦🇹Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Med.Univ.Graz, Univ.-Klinikum f. Innere Medizin, Klin. Abt. f. Haematologie, Graz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.